Cencora
COR
Market cap $44B

227.69 USD

+1.42

0.63%

At close Dec 20, 4:00 PM EST

After hours

228.99

+1.30

0.57%

1 day

0.63%

5 days

-2.24%

1 month

-6.38%

3 months

-0.18%

6 months

-3.39%

Year to date

9.18%

1 year

13.96%

5 years

27.27%

10 years

100.94%

About: Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the us pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.

Employees: 46,000

Healthcare Drugs, Proprietaries & Druggists Sundries

0

Funds holding %

of 6,809 funds

0

Analysts bullish %

of 6 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

106% more call options, than puts

Call options by funds: $1.69B | Put options by funds: $819M

20% more repeat investments, than reductions

Existing positions increased: 455 | Existing positions reduced: 380

20% more first-time investments, than exits

New positions opened: 128 | Existing positions closed: 107

2% more funds holding

Funds holding: 1,115 [Q2] → 1,136 (+21) [Q3]

5% less capital invested

Capital invested by funds: $45.2B [Q2] → $43.1B (-$2.12B) [Q3]

3.44% less ownership

Funds ownership: 100.58% [Q2] → 97.14% (-3.44%) [Q3]

17% less funds holding in top 10

Funds holding in top 10: 18 [Q2] → 15 (-3) [Q3]

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$237

4%

upside

Avg. target

$277

22%

upside

High target

$292

28%

upside

6 analyst ratings

5 positive

83%

1 neutral

17%

0 negative

0%

Wells Fargo Eric Luebchow 62% 1-year accuracy 26 / 42 met price target	4%upside $237	Equal-Weight Maintained	13 Dec 2024
Baird David Rodgers 48% 1-year accuracy 10 / 21 met price target	28%upside $292	Outperform Maintained	7 Nov 2024
UBS Kevin Caliendo 56% 1-year accuracy 9 / 16 met price target	25%upside $285	Buy Maintained	7 Nov 2024
Barclays Stephanie Davis 56% 1-year accuracy 9 / 16 met price target	27%upside $290	Overweight Maintained	7 Nov 2024
Evercore ISI Group John Belton 67% 1-year accuracy 2 / 3 met price target	25%upside $285	Outperform Maintained	7 Nov 2024

See Analyst Rankings

Financial journalist opinion

Based on 12 articles about COR published over the past 30 days

Zacks Investment Research

Why Cencora (COR) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Cencora (COR) is a Top Growth Stock for the Long-Term

Zacks Investment Research

Here's Why You Should Hold Cencora Stock in Your Portfolio for Now

COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Here's Why You Should Hold Cencora Stock in Your Portfolio for Now

Zacks Investment Research

Here's Why Cencora (COR) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Cencora (COR) is a Strong Value Stock

Cencora Closes $1.8 Billion Senior Notes Offering

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced the closing of its public offering of $500,000,000 aggregate principal amount of its 4.625% Senior Notes due December 15, 2027 (the “2027 Notes”), $600,000,000 aggregate principal amount of its 4.850% Senior Notes due December 15, 2029 (the “2029 Notes”) and $700,000,000 aggregate principal amount of its 5.150% Senior Notes due February 15, 2035 (the “2035 Notes” and, together with the 2027 Notes and the 2029 Notes, t.

Cencora Closes $1.8 Billion Senior Notes Offering

Cencora Launches Accelerate Pharmacy Solutions to Enhance Support for Hospital and Health System Customers

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, a global healthcare company, announced the launch of Accelerate Pharmacy Solutions, a unified portfolio of solutions designed to help hospital and health systems customers optimize operations and improve financial performance. Accelerate Pharmacy Solutions brings together Cencora's suite of pharmacy and supply chain solutions, enabling Cencora to deliver an enhanced customer experience and integrated support to address customers' evolving needs. The.

Cencora Launches Accelerate Pharmacy Solutions to Enhance Support for Hospital and Health System Customers

Cencora: Competitive Advantages Defined

Cencora is a 'super cash cow' with high capital turnover and low margins, generating substantial free cash flow from its competitive advantages. COR's business model thrives on low-cost operations, ensuring resilience in both high and low pricing environments. Despite inflation risks, COR's negative net working capital and efficient capital allocation enhance its ability to grow and generate cash.

Cencora: Competitive Advantages Defined

Cencora Prices $500 Million 4.625% Senior Notes Due 2027, $600 Million 4.850% Senior Notes Due 2029 and $700 Million 5.150% Senior Notes Due 2035

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it priced $500 million aggregate principal amount of its 4.625% Senior Notes due December 15, 2027 (the “2027 Notes”), $600 million aggregate principal amount of its 4.850% Senior Notes due December 15, 2029 (the “2029 Notes”) and $700 million aggregate principal amount of its 5.150% Senior Notes due February 15, 2035 (the “2035 Notes” and, together with the 2027 Notes and the 2029 Notes, the “Notes”), in an unde.

Cencora Prices $500 Million 4.625% Senior Notes Due 2027, $600 Million 4.850% Senior Notes Due 2029 and $700 Million 5.150% Senior Notes Due 2035

Zacks Investment Research

Here's Why Cencora (COR) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Cencora (COR) is a Strong Momentum Stock

Cencora to Host Inaugural Product Showcase

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, a global healthcare company, will host its inaugural Product Showcase, an event that will provide increased visibility into the company's portfolio of solutions and the products it's developing to support the evolving needs of its customers. During the virtual event, scheduled for December 3 at 11:00am ET, Cencora executives and leaders from across the organization will highlight innovative partnerships and provide updates on new product offerings. T.

Cencora to Host Inaugural Product Showcase

Zacks Investment Research

Why Cencora (COR) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Cencora (COR) is a Top Value Stock for the Long-Term

See News Rankings

Charts implemented using Lightweight Charts™